| 摘要 |
Methods and materials are provided for determining the responsiveness of a subject to a therapy, such as an antibody therapy and for selecting and/or for treating a subject based on an FcγRIIA polymorphism, or an FcγRIIIA polymorphism, or both an FcγRIIA polymorphism and an FcγRIIIA polymorphism, including where the treatment is an therapy, such as rituximab. Methods and materials are also provided for designing, making, screening, testing and/or administering antibodies as well as for optimizing antibody therapies based upon a subject's FcγRIIA polymorphism, or FcγRIIIA polymorphism, or both the FcγRIIA polymorphism and the FcγRIIIA polymorphism. |
